INTRODUCTION
Autologous stem cell transplantation (ASCT) is widely used as part of first line therapy in the treatment of younger, transplant eligible patients with MM. 1, 2 In these patients, stem cell (SC) mobilization for ASCT has commonly been performed using cyclophosphamide plus G-CSF(C+G-CSF) or G-CSF alone. The failure rate ranges from 5 to 15% using these agents for SC mobilization. [3] [4] [5] [6] This concern has been especially pertinent to patients previously exposed to multiple cycles of lenalidomide during induction treatment as this drug appears to hamper SC mobilization, at least when using G-CSF alone as a mobilizing agent. [7] [8] [9] [10] International Myeloma Working Group consensus recommendations favor, in these patients, the use of C+G-CSF, the regimen currently most widely used for SC mobilization in patients with MM. 11 Plerixafor (Mozobil, Sanofi, Cambridge, MA, USA) is a small molecule that reversibly disrupts the interaction of CXCR4 with its ligand SDF-1, allowing the release of SCs from the marrow. 12 It is approved for SC mobilization in combination with G-CSF (P+G-CSF) for both MM and non-Hodgkin's lymphoma patients. 13, 14 It is highly active and has been shown, in a phase III clinical trial, to yield more SCs in fewer apheresis sessions compared with G-CSF alone when used in MM patients. 14 In addition, plerixafor was shown to rescue patients who failed mobilization with G-CSF with or without cyclophosphamide. [15] [16] [17] [18] [19] Despite the proven efficacy of P+G-CSF in upfront SC mobilization, its use for this indication has been limited, mostly due to concerns of high price of the drug. To overcome this hurdle, investigators have proposed 'on demand' use of plerixafor in patients identified to have inadequate SC mobilization with G-CSF, with the assumption that such an approach promotes cost containment by limiting plerixafor use but taking advantage of its efficacy in patients in whom poor mobilization is anticipated. 20 In addition, since cyclophosphamide is considered important for SC mobilization in patients with MM, most of whom get exposed to lenalidomide during induction, the same plerixafor 'on demand' approach has also been tested following C+G-CSF. 5, [21] [22] [23] [24] However, this approach is based on the premise that upfront chemotherapy mobilization is more cost effective than upfront plerixafor mobilization, an assumption that has not been adequately tested. Thus far, there are no definitive studies comparing the mobilization effectiveness, and importantly, the cost effectiveness of C+G-CSF versus P+G-CSF as mobilization regimens.
At Memorial Sloan Kettering Cancer Center (MSKCC), the use of plerixafor for upfront SC mobilization has significantly increased in recent years mainly due to the perceived greater risk of toxicities and infections following chemotherapy mobilization. Here we report a retrospective data analysis comparing efficacy, toxicity and financial burden of P+G-CSF and C+G-CSF when used as part of upfront SC mobilization strategy in a single institution. We also compare engraftment outcomes using either SC mobilization approach.
MATERIALS AND METHODS

Patient selection and data collection
Institutional Review Board protocol approval and a waiver of informed consent were obtained before database query. We identified all patients with a diagnosis of MM who received C+G-CSF or P+G-CSF as mobilization regimens for SC collection from the time period between 1 November 2008 and 1 June 2012, using the MSKCC pharmacy database. Patients who had completed prior SC mobilization were excluded.
Patients' baseline characteristics included the following: age; gender; International staging system score at diagnosis; prognostic risk at diagnosis based on cytogenetics; laboratory values including lactic acid dehydrogenase, ß2 microglobulin, albumin, white blood cell (WBC) and platelet count; and percentage of plasma cells in the bone marrow before mobilization. Patients' treatment characteristics included the following: type of induction treatment administered noting any exposure to lenalidomide; number of induction cycles administered; time from induction treatment to start of mobilization; and time between end of induction treatment and the start of mobilization.
Mobilization regimens and strategy
During the study period, two standardized mobilization regimens were in use at MSKCC for upfront mobilization: cyclophosphamide-and plerixaforbased mobilizations. During this period that followed the FDA approval of plerixafor, the choice of mobilization regimen was primarily based on physician preference but also driven, in significant part, by clinical trialsmost mandating the use of cyclophosphamide-as well as insurance constraints since all third party payers had yet to accept the upfront use of plerixafor for SC mobilization.
Patients mobilized with P+G-CSF, received G-CSF 10 mcg/kg subcutaneously for 4 consecutive days starting on day 1. On the evening of day 4, plerixafor 0.24 mg/kg was administered, 11 h before initiation of apheresis. Apheresis was initiated on day 5 if peripheral blood CD34+ cell count was ⩾ 5 cells/mcL on that day. Plerixafor, G-CSF and apheresis were repeated on subsequent days until the target number of SCs was reached (up to a maximum of four apheresis sessions) (Figure 1 ). Patients mobilized with C +G-CSF received cyclophosphamide 3 g/m 2 on day 1, followed by subcutaneous G-CSF 10 mcg/kg for 10 days starting on day 2. Apheresis was scheduled to start on day 12 if peripheral blood CD34+ cell count was 45 cells/mcL on that day. Daily G-CSF and apheresis were repeated on subsequent days until the target number of SCs was reached (up to a maximum of five apheresis sessions). Both mobilization regimens were given in the outpatient setting with standard supportive care implemented. In the cyclophosphamide group, all patients received antiemetic prophylaxis with intravenous ondansetron before chemotherapy along with hydration, Mesna, furosemide and dexamethasone. In addition, all patients who received cyclophosphamide received antimicrobial prophylaxis with levofloxacin or ciprofloxacin and fluconazole for 10 days.
Patients who were deemed to have failed upfront SC collection as determined by their treating physician had a second attempt at SC collection (referred to thereafter as salvage SC mobilization and collection). For salvage mobilization, patients who failed upfront C+G-CSF mobilization were remobilized with either P+G-CSF or C+G-CSF with the addition of plerixafor (and for one patient the addition of bortezomib), based on physician preference. As for patients who failed upfront P+G-CSF mobilization, they were remobilized with either chemotherapy+G-CSF (which included cyclophosphamide or VDT-PACE (velcade, dexamethasone, thalidomide, cisPlatin, doxorubicin (adriamycin), cyclophosphamide, etoposide) chemotherapy) or remobilized with P+G-SCF with the addition of cyclophosphamide.
The standard number of SCs targeted for at the conclusion of the upfront SC collection attempt was set at 10 × 10 6 CD34+ cells/kg due to the anticipation of potentially performing two ASCT during the course of treatment. Patients collecting o5 × 10 6 CD34+ cells/kg during the upfront SC collection procedure were considered mobilization failures for the purpose of this analysis. The final products were cryopreserved in 10% DMSO using a controlled rate freezer and stored in liquid nitrogen.
Financial analysis
Data on financial burden incurred during the mobilization and apheresis processes were analyzed for all patients in both the P+G-CSF group and the C+G-CSF group. The financial analysis included all billable services related to mobilization, apheresis cell processing and associated clinical events including subsequent hospitalizations due to complications.
The analysis examined the financial burden of the two mobilization regimens from three perspectives: institutional charges, institutional costs and Medicare reimbursement. Because our primary concern was the financial implication relating to our own institution, we first compared the regimens using both institutional charges and costs, with institutional costs being derived from billed charges using cost to charge ratios specific to each department. All costs were normalized and adjusted based on institutional charges and costs for 2012, and drug dosages were standardized to a body mass index of 2 m 2 , or 75 kg. CY is administered on day 1 followed by G-CSF initiated on day 2 until day 11; apheresis is started on day 12; G-CSF and apheresis are repeated on subsequent days until the target number of stem cells is reached, up to a maximum of four apheresis sessions.
Because of the limitations of institution-specific charge and cost data, with charges being highly variable among different institutions and institutional costs being proprietary and not generalizable, we chose to perform the analysis using standard reimbursement data from the Centers for Medicare and Medicaid Services (CMS) as a proxy for cost (Table 1) . Median national CMS Outpatient Prospective Payment System rates for July 2012 were used to determine mobilization and apheresis reimbursements, while related hospitalization reimbursements were calculated based on the 2012 inpatient prospective payment system diagnosisrelated group rates. The prices of medications, including chemotherapeutic agents, mobilizing growth factors and supportive medications, were based on the average sale price for July 2012 as published on the CMS website. Laboratory reimbursements were derived from the 2012 Medicare Clinical Lab Fee Schedule.
Engraftment
For patients who proceeded to transplantation, the date of transplantation, number of cells infused and time to neutrophil and platelet engraftment were collected. Time to neutrophil engraftment was defined as time from conditioning regimen to an absolute neutrophil count of 500 or greater for 2 consecutive days. Time to platelet engraftment was defined as time from conditioning regimen to last platelet transfusion. Per institutional guidelines, most patients are routinely transfused if platelet count is o10 000/mcL.
Statistical analysis
Descriptive statistics were used to compare patients' baseline and treatment characteristics in both groups. A Wilcoxon rank-sum test was used to compare continuous variables across the two groups, while Fisher's exact test or a χ 2 test was used to compare categorical factors, as appropriate. All analyses were conducted using the R statistical package v 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).
RESULTS
Patients' baseline and treatment characteristics
The baseline and treatment characteristics for the 223 patients with MM included in the analysis are shown in Table 2 . One hundred and twelve patients received P+G-CSF for mobilization, and 111 patients received C+G-CSF. Patients in the two arms were well matched for age, gender, platelet count before collection, International staging system staging, risk factor profile, prior lenalidomide exposure, number of induction cycles received before collection, time between start of induction and SC collection. The two populations were significantly different in terms of WBC and percent of plasma cells in the bone marrow before collection (P = 0.003 and o 0.01, respectively).
SC collection efficiency
The median number of SCs collected/kg for the P+G-CSF arm and C+G-CSF arm were not significantly different (11.39 × 10 6 and 10.9 × 10 6 CD34+ cells/kg, respectively, (P = 0.290)). The mean number of days of apheresis showed no difference between the 2 groups, with 2.3 days for the P+G-CSF group and 2.6 days for the C+G-CSF group (P = 0.405). The SC collection efficiency, defined as the number of SCs collected per apheresis session, was 5.6 with P +G-CSF and 5.0 in the C+G-CSF treated patients (P = 0.230). Importantly, more patients in the P+G-CSF group achieved a successful collection (defined as a minimum of 5 × 10 6 CD34+ cells/kg) than in the C+G-CSF group (105 out of 112 (94%) and 92 out of 111 (83%), (P = 0.013), respectively; Table 3 ). Note that if a less stringent number for SC collection was chosen (minimum of 4 × 10 6 CD34+ cells/kg as set by other institutions as it is the minimum number of SCs required for two ASCTs), 108 out of 112 (96%) and 95 out of 111 (85%; P = 0.005), would have achieved successful SC collection for the P+G-CSF and the C+G-CSF groups, respectively.
Five patients in the P+G-CSF and 20 patients in the C+G-CSF group needed a salvage SC collection, as the number of SCs collected during the initial mobilization attempt was deemed insufficient by the treating physician. It is important to note that if a threshold of 4 × 10 6 CD34+ cells/kg were to be used systematically as a trigger to plan a salvage collection, then 4 and 16 patients would have been scheduled for salvage SC collection in the P+G-CSF and C+G-CSF groups, respectively. In addition, the C Toxicity There were no hospitalizations or major complications related to mobilization in the P+G-CSF group. There were 13 admissions following cyclophosphamide administration in the C+G-CSF chemotherapy group, 8 of which were related to infections and febrile neutropenia. Other causes for hospital admission in this group included renal failure, stroke, severe dyspnea requiring ICU admission and nausea/vomiting. All these patients were admitted an average of 7.8 days after cyclophosphamide administration. The average length of stay for all 13 patients was 6.6 days. One of these hospitalizations resulted in a delay in SC collection and required readministration of cyclophosphamide for collection.
Financial analysis When we evaluated charges relating to mobilization, apheresis cell processing and associated clinical events, the difference between the two mobilization regimens was statistically significant. The charges per patient for the C+G-CSF group was 1.3 times higher than for the P+G-CSF group ($72 138 vs $52 200 P = o 0.001) ( Table 4 ). In addition, we found a significant difference in total cost of mobilization between the two groups when using specific departmental cost to charge ratios to convert the charges to cost (P o 0.0001), although the results are not reported as they are proprietary and cannot be made public. When the charges associated with salvage apheresis are discounted for the 20 patients in the C+G-CSF group who failed first SC mobilization, assuming that these patients could have been spared a second set of salvage apheresis if plerixafor 'on demand' had been implemented, the charge per patient in the C+G-CSF group remains 1.26 times greater (P = 0.019) than that of the P+G-CSF group. There was no statistically significant difference in mean or median total reimbursement for mobilization between the P+G-CSF and C+G-CSF mobilized patient groups when using Medicare reimbursement as a proxy for cost. Although not statistically significant, Medicare reimbursement per patient was 8.6% higher in the C+G-CSF group versus the P+G-CSF group ($22 959 vs $21 144; P = 0.27). As detailed in Table 5 , patients receiving C+G-CSF consumed more resources, had significantly more complications and hospitalizations, more salvage mobilization and collections, and more G-CSF use than those treated with P+G-CSF.
Engraftment results
Ninety-five patients from each group proceeded to high-dose therapy with melphalan and ASCT ( Table 6 ). All other patients Efficacy and cost of plerixafor and cyclophosphamide mobilization S Afifi et al were only collected with the goal of ASCT at a future date. Platelet and neutrophil engraftment occurred in all transplanted patients. Median time to platelet engraftment was not significantly different in the C+G-CSF group (median 11 days, range 4-36 days) compared with the P+G-CSF group (median 12 days, range 6-47 days; P = 0.37). Median time to neutrophil engraftment was not significantly different in the two arms (median 10 days, (range 8-20 days) vs 11 days, (range 3-32), respectively, (P = 0.167).
DISCUSSION
Multiple myeloma is one of the most common indications for peripheral blood SC mobilization and collection. The field of SC mobilization is being reshaped by the introduction of plerixafor, a highly effective but expensive agent. Despite the proven efficacy of plerixafor, chemotherapy combined with G-CSF remains one of the most standard mobilization strategies for patients with MM in most transplant centers. The resilience of this mobilization strategy is most likely a result of the high price of the drug plerixafor and the well-established track record of chemotherapy mobilization, which provides better CD34+ cell yield and fewer apheresis sessions when compared with G-CSF alone. In addition, this chemotherapy mobilization strategy has the potential to overcome the difficulty in collecting SC from patients previously exposed to lenalidomide. 7, 10, 25 However, the use of chemotherapy +G-CSF as a mobilization strategy is not without risk. Studies have shown significant toxicity associated with chemotherapy administration during mobilization of SCs, including neutropenic fever and sepsis, leading to increased risk of morbidity and mortality, as well as increased healthcare cost. 26, 27 The use of P+G-CSF in the upfront setting has the potential to overcome the disadvantages of growth factor only mobilization, sparing patients the toxicities associated with chemotherapy use.
In this retrospective analysis, we have shown that upfront mobilization with P+G-CSF is associated with a better clinical outcome than with C+G-CSF in terms of percentage of SC collection failure as well as complications. The use of P+G-CSF mobilization resulted in decreased mobilization failure (when defined as o 5 × 10 6 or 4 × 10 6 CD34+ cells/kg collected). Despite this advantage of P+G-CSF, the median number of total CD34+ cells/kg collected per patient did not statistically differ between the two groups. This finding is likely due to the compensation afforded by a slight increase in apheresis sessions in the C+G-CSF group. We believe that the difference in this clinical outcome cannot be attributed to differences between the two groups, as they were fairly comparable in terms of patient baseline and treatment characteristics, including prior exposure to lenalidomide. Baseline WBC and bone marrow plasmacytosis were the only baseline characteristics with a statistical dissimilarity between the two groups. However, a study conducted at our institution by Pozotrigo et al. 28 noted that older age, lower platelet count and single use of G-CSF (without cyclophosphamide) were the only risk Two patients who were transplanted and for whom the number of stem cells transfused is unknown have been removed from analysis. b Four patients who were never transfused were removed from analysis.
Efficacy and cost of plerixafor and cyclophosphamide mobilization S Afifi et al factors associated with mobilization failure or low efficiency in a large group of patients mobilized at MSKCC before the introduction of plerixafor. Therefore, it is unlikely that WBC count and bone marrow plasmacytosis would have biased the clinical outcome of the current analysis. We found a statistically higher financial burden associated with the C+G-CSF group when compared with the P+G-CSF group in respect to charges and derived institutional costs. When considering Medicare reimbursement, although the difference in favor of the P+G-CSF regimen persists, it was not statistically significant. The higher price of plerixafor was offset by the increased G-CSF use, increased number of apheresis sessions, hospitalizations associated with cyclophosphamide complications, and increased mobilization failures resulting in need for salvage mobilization in the C+G-CSF group.
Previously reported studies have compared both clinical effectiveness and financial burden of plerixafor versus chemotherapy mobilization regimens. Shaughnessy et al. 29 found a significantly higher percentage of patients collecting ⩾ 5 × 10 6 cells/kg in the plerixafor group compared with the cyclophosphamide group (94 vs 76%). Despite a higher cost associated with SC mobilization for the cyclophosphamide group as compared with the plerixafor group, the difference was not statistically significant. This was likely due to the small number of patients included in the study (n = 66). It is important to note that the patients analyzed in this study included those with diagnoses of MM and non-Hodgkin's lymphoma. Therefore the SC collection requirement in this study was set at 2 × 10 6 CD34+ cells/kg, a level that may not be adequate for MM patients. This lower threshold may explain the lack of need for salvage collection reported in this patient population. Costa et al. 30 compared standard cyclophosphamide mobilization versus an algorithm using G-CSF plus 'on demand' plerixafor, an approach that would be expected to further lower the financial burden of plerixafor mobilization when compared with the approach used in the current study, as a significant percentage of patients would be spared plerixafor. The authors reported a significantly higher rate of mobilization failure with the cyclophosphamide-based regimen. 14, 30 An 'estimated cost' analysis (rather than actual cost) did not find a difference between the two arms, although it did not include the cost of re-mobilization. Therefore an estimated average cost per patient successfully mobilized was performed and favored the plerixafor arm. Micallef et al. 17 have developed and evaluated a similar risk-adapted algorithm using on demand plerixafor for optimal utilization of the drug. They compared this approach to the standard G-CSF and chemo-G-CSF and concluded that the earlier identification of ineffective SC mobilization and initiation of plerixafor 'on demand' lowers the failure rate, days of apheresis and total days of mobilization/collection, but increases the per patient costs of SC mobilization. 17 The cost of hospitalization and complications were not included in that analysis, which may partly explain their findings.
On the other hand, Awan et al. compared the efficacy and cost of SC mobilization with intermediate-dose CY and G-CSF versus plerixafor and G-CSF in MM patients. The authors reported a higher CD34+ cell yield on day 1 and higher total yield (16.6 × 10 6 vs 11.6 × 10 6 cells/kg, P o0.001) in the non-plerixafor group, yet more G-CSF usage. 31 In addition, the authors noted that cyclophosphamide was associated with a significantly lower average total cost of mobilization. This latter observation may, at least partially, be attributed to the unusual absence, at odds with all studies, of mobilization failure and subsequent need for salvage mobilization.
It is also important to note that the rates of hospitalization with cyclophosphamide in the studies listed above ranged from 20 to 58%, compared with 11% in the current study. 14, 30, 31 Such high rates of hospitalization, if more representative of other institutions, would result in even higher financial burden in the C+G-CSF group. In addition, more important than financial burden, is the safety and quality of life for patients undergoing SC mobilization. We venture to extrapolate from the findings in the current studyas a quality of life was not performed-that a lower toxicity and higher quality of life would be anticipated with plerixafor.
We acknowledge that differences between institutions could positively or negatively impact on the financial burden of mobilization. Various clinical practices, like delaying the start of G-CSF until several days after cyclophosphamide administration, using lower doses of G-CSF or cyclophosphamide, changing the threshold of peripheral CD34+ cell count used to start apheresis, and certainly the use of on demand plerixafor, may affect the cost benefit ratio. Likewise, the acquisition price of these drugs will vary between institutions as it is dependent on volume of drug purchased and applied discounts, incentives and rebates. Because hospital charges fluctuate widely between institutions, we have chosen to report Medicare reimbursement rates for the mobilization, apheresis cell processing and associated clinical events, including subsequent hospitalizations due to complications, in addition to institutional charges and costs for these same procedures.
In conclusion, this retrospective study indicates that P+G-CSF used for upfront SC mobilization provides a higher rate of mobilization success, leads to fewer complications resulting from toxicity, and results in similar transplant engraftment outcomes when compared with C+G-CSF. The study indicates that institutional costs and charges are significantly reduced by the use of P +G-CSF when compared with C+G-CSF, with the latter approach being associated with higher resource utilization likely due to its lesser efficiency and increased rate of complications. This difference persists, although not statistically significant, when CMS reimbursement data are analyzed. Although we acknowledge the limitations of this retrospective analysis, this study, along with the findings of other investigators pertaining to 'on demand' plerixafor, strongly support the use of upfront P+G-CSF in MM, with the anticipation that the incorporation of 'on demand' plerixafor could only further improve the cost benefit ratio. On the basis of retrospective analysis, we have widely adopted at MSKCC, the use of P+G-CSF upfront in patients with MM.
